Drug intelligence / Profile preview

QL-115

Development stage: Unknown
Lead developer: Shenzhen Qinglan Biotechnology
Modality: Peptides
Administration: Transdermal

Overview

QL-115 is a peptide-based glucagon-like peptide-1 (GLP-1) receptor agonist developed by BioQingLam for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The drug is formulated as a transdermal soluble microneedle patch, utilizing the company's proprietary delivery platform to provide a non-invasive alternative to subcutaneous injections. By activating the GLP-1 receptor, QL-115 stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby improving glycemic control and promoting weight loss. It is currently in Phase III clinical development.

Other names: QL-115 soluble microneedle patchQL115 soluble microneedle patchQL 115 soluble microneedle patch

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on QL-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-115.

Explore the full profile